Paolo Pozzilli

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +9

C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

Jerry P. Palmer, G. Alexander Fleming, Carla J. Greenbaum et al. · Diabetes · 2004 · 476 citations · Full text

Diabetes Clinical Trials, Immunology, Underlying Cause +16

A functional variant of SUMO4, a new IκBα modifier, is associated with type 1 diabetes

Dehuang Guo, Manyu Li, Yan Zhang et al. · Nature Genetics · 2004 · 420 citations

Metabolic Syndrome, Type 1, Signal Transduction +9

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

Satish K. Garg, Robert R. Henry, Phillip Banks et al. · New England Journal of Medicine · 2017 · 400 citations · Full text

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Antoinette Moran, Brian N. Bundy, Dorothy Becker et al. · The Lancet · 2013 · 351 citations · Full text

Inflammation, Metabolic Syndrome, Type 1 +11